← SynDRA
CYC-116
SynDRA canonical compound SYN0018869 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | AURKA | AURKB | AURKC | KDR |
|---|
| Mechanism of action | Aurora kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- AURKB INHIBITOR
- Serine/threonine-protein kinase Aurora inhibitor
- AURKC INHIBITOR
- AURKA INHIBITOR
- KDR INHIBITOR
- Vascular endothelial growth factor receptor 2 inhibitor
- aurora kinase inhibitor
Cross-references
Synonyms
- CYC116
- CYC 116
- CHEMBL482967
- Kinome_636
- 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine
- 4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amine
- 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine
- 4-methyl-5-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)thiazol-2-amine
- 2uue
- GPSZYOIFQZPWEJ-UHFFFAOYSA-N
- 2c5t
- AC1O4WKE
- MLS006011244
- SCHEMBL2074998
- SYN1034
- EX-A753
- CYC-116/CYC116
- MolPort-009-679-476
- HMS3244O12
- HMS3244P11
- BCPP000273
- YAX4981K2D
- CYC-116(Antitumor)
- UNII-YAX4981K2D
- CYC 116 [WHO-DD]
- HMS3244O11
- HMS3654O14
- BCP01887
- ZINC3950132
- BDBM50277583
- MFCD14155805
- NSC759498
- NSC800082
- s1171
- 4-(2-amino-4-methylthiazol-5-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine
- AKOS015897897
- BCP9000562
- CCG-264845
- CS-0112
Look up CYC-116 in the interactive SynDRA portal →